Challenge 7

Scalable Manufacturing Process for Proposed Anti-SARS-CoV-2 Vaccine

A Phase 1 clinical trial evaluating a vaccine against COVID-19 has recently begun. The vaccine is called mRNA-1273 and was developed by scientists at the US National Institute of Allergy and Infectious Diseases in collaboration with a biotechnology company, Moderna, Inc.
The mRNA-1273 vaccine is comprised of a novel lipid nanoparticle-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike protein (S) of the SARS-CoV-2 virus that causes COVID-19. The mRNA delivered by the viral vaccine directs cells within the body to express the S protein that it is hoped will elicit a robust immune response.

If approved, the world will likely require the mRNA-1273 vaccine to be produced and made available in large quantities, and fast. The focus of this challenge is therefore to propose a workable Process Flow Diagram for the large-scale production of the mRNA-1273 vaccine should it pass clinical trials and become clinically available.

Who Can Compete: All MEng, MSc, MASc and PhD students in CHBE
What and Where Do You Submit: A PDF proposal and engineering justification of no more than 5 pages
When is it Due: May 15, 2020 by 5 pm
To Whom Do I submit: Vikram Yadav (vikramaditya.yadav@ubc.ca)
What is the Prize: $100 VISA gift card